The significant number of diseases with no effective treatment is the inspiration for Cell2B. Its founders believe in the power of cells to fight diseases and they are currently developing ImmuneSafe®, which presented promising results in a small clinical study.
This cell product will undergo clinical trials for the treatment of acute Graft-versus-Host-Disease (GvHD), a major complication of bone marrow transplantation, with unmet clinical response.
Cell2B is a biotech developer of cell therapies for immune and inflammatory diseases, with technology developed by its founders and licensed from the Massachusetts Institute of Technology in Boston and Instituto Superior Técnico in Lisbon.
In the fundraising process, Shilling has been very helpful, establishing lots of contacts with potential investors, and supporting us in the negotiations by defending the best interests of the company.